What is CLYM's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.63B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CLYM?

P/E (TTM) is n/a and 52-week range is $1.64 to $18.33 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CLYM figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CLYM?

The company profile lists net income (TTM) near $-47M, EPS (TTM) near $-0.82 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Climb Bio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Wellesley Hills, Massachusetts, US, 57.3M shares outstanding, ISIN US28658R1068 when available from company profile and filing metadata.

Climb Bio Inc

$CLYM

Health Care · Biotechnology

IR Run Scenarios

$11.00

+1.29%

Climb Bio Inc

$CLYM

Health Care · Biotechnology

IR Run Scenarios

$11.00

+1.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Employees

29

Website

climbbio.com/

IPO

2021-08-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US28658R1068

Headquarters

Wellesley Hills, Massachusetts, US

Shares outstanding

57.3M

NAICS sector

Professional, Scientific, and Technical Services

Institutional ownership

105.29%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Employees

29

Website

climbbio.com/

IPO

2021-08-10

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)